➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Harvard Business School
Colorcon
Mallinckrodt
Johnson and Johnson

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for CT1812


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug CT1812?

CT1812 is an investigational drug.

There have been 7 clinical trials for CT1812. The most recent clinical trial was a Phase 1 trial, which was initiated on July 30th 2020.

The most common disease conditions in clinical trials are Alzheimer Disease, Cognition Disorders, and [disabled in preview]. The leading clinical trial sponsors are Cognition Therapeutics and [disabled in preview].

There are three US patents protecting this investigational drug and eighteen international patents.

Recent Clinical Trials for CT1812
TitleSponsorPhase
Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEGCognition TherapeuticsPhase 2
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.Cognition TherapeuticsPhase 2
Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's DiseaseCognition TherapeuticsPhase 1

See all CT1812 clinical trials

Clinical Trial Summary for CT1812

Top disease conditions for CT1812
Top clinical trial sponsors for CT1812

See all CT1812 clinical trials

US Patents for CT1812

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CT1812   Get Started Free Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. (Pittsburgh, PA)   Get Started Free
CT1812   Get Started Free Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. (Pittsburgh, PA)   Get Started Free
CT1812   Get Started Free Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. (Pittsburgh, PA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CT1812

Drugname Country Document Number Estimated Expiration Related US Patent
CT1812 Australia AU2015210852 2034-01-31   Get Started Free
CT1812 Brazil BR112016017808 2034-01-31   Get Started Free
CT1812 Canada CA2938212 2034-01-31   Get Started Free
CT1812 China CN106163516 2034-01-31   Get Started Free
CT1812 Denmark DK3099296 2034-01-31   Get Started Free
CT1812 European Patent Office EP3099296 2034-01-31   Get Started Free
CT1812 European Patent Office EP3498692 2034-01-31   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Johnson and Johnson
Colorcon
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.